调节线粒体中的Lars2:通过抑制陶酸化来作为潜在的阿尔茨海默病治疗方法
Wenqi Qian1, Lin Yuan2, Weishan Zhuge3
1Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
概括
研究人员将Lars2确定为潜在的阿尔茨海默病 (AD) 目标. 这种酶的下调会损害线粒体功能,导致蛋白酸化和神经元死亡,这表明Lars2是治疗候选者.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 缺乏有效的治疗方法,需要新的治疗点.
- 拉斯2是一种对线粒体leucyl-tRNA合成和功能至关重要的酶,正在研究其在AD病变发生中的作用.
研究的目的:
- 确定Lars2作为阿尔茨海默病的潜在治疗点.
- 阐明将Lars2功能障碍与AD病理联系起来的分子机制.
主要方法:
- 人类大脑转录组数据的生物信息学分析.
- 在神经母细胞瘤和初级皮质神经元中,Lars2的体外淘汰.
- 在小鼠海马神经元中Lars2的体内淘汰.
- 使用行为测试评估认知功能 (巴恩斯迷宫,新型对象识别,筑巢).
- 免疫光测试检测p-tau和神经元形态.
主要成果:
- 拉斯2在阿尔茨海默病患者的大脑中被下调.
- 拉斯2 knockdown 诱导了神经元形态变化和密度下降.
- 拉斯2的降低调节损害了PI3K-AKT通路,激活了GSK3β,导致陶过酸化.
- 在老鼠中,Lars2淘汰会导致认知缺陷,海马缩和神经元损失.
结论:
- 拉斯2在维持神经元功能和线粒体健康方面发挥着至关重要的作用.
- 拉斯2的失调有助于阿尔茨海默病的病原因通过的过酸化和神经退行.
- 拉斯2抑制PI3K-AKT通路是AD进展的关键机制.
- 拉斯2代表了阿尔茨海默病治疗的有前途的治疗标.
相关概念视频
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K


